Macrilen

MACRILEN- macimorelin granule, for solution
Strongbridge U.S. Inc

1 INDICATIONS AND USAGE

MACRILEN is indicated for the diagnosis of adult growth hormone deficiency (AGHD).

Limitations of Use

The safety and diagnostic performance of MACRILEN have not been established for subjects with a body mass index (BMI) > 40 kg/m2.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dose

The recommended dose is a single oral dose of 0.5 mg/kg of macimorelin. The dose is administered as a reconstituted solution [see Dosage and Administration (2.3)] in patients fasted for at least 8 hours.

2.2 Important Recommendations Before MACRILEN Use

Discontinue strong CYP3A4 inducers prior to MACRILEN use [see Warning and Precautions (5.2) and Drug Interactions (7.2)].
Discontinue growth hormone (GH) therapy at least one week before administering MACRILEN [see Drug Interactions (7.3)].
Avoid the use of MACRILEN with drugs known to affect pituitary GH secretion [see Drug Interactions (7.3)].
For patients with deficiencies in sex hormones, thyroid hormone and/or glucocorticoid, adequately replace each of the missing hormones before administering MACRILEN.
Ensure that the patient has fasted for at least 8 hours before MACRILEN use.

2.3 Directions for Preparation and Administration

Prepare and administer by a healthcare professional exactly as follows.

Prepare the MACRILEN solution:

a.
Weigh the patient in kilograms (i.e., kg).
b.
Determine the number of MACRILEN pouches needed to prepare the dose:
i. For a patient weighing up to 120 kg, use 1 pouch.
ii. For a patient weighing more than 120 kg, use 2 pouches.
c.
Use a glass or transparent plastic container with graduation in milliliters (i.e., mL) to dissolve the entire contents of the pouch(es) in the appropriate volume of water.
i. For 1 pouch dissolve in 120 mL of water (corresponds to 60 mg/120 mL).
ii. For 2 pouches dissolve in 240 mL of water (corresponds to 120 mg/240 mL).
d.
Stir the MACRILEN solution gently for about 2 to 3 minutes (a small amount of un-dissolved particles will remain). The solution will have a final concentration of 0.5 mg/mL.
e.
Use the MACRILEN solution within 30 minutes after preparation.
f.
Discard any unused MACRILEN solution.

Determine the volume of MACRILEN solution needed for the test:

g.
Determine the recommended dose to be administered by multiplying the patient weight in kilogram by 0.5 mg/kg.

For example, a 70 kg patient will need a 35 mg dose.

h.
Determine the volume of prepared MACRILEN solution to be administered by dividing the recommended dose by 0.5 mg/mL.

For example, a patient requiring a dose of 35 mg will need 70 mL of reconstituted MACRILEN solution.

i.
Use a syringe (without a needle) with graduations in mL to measure the exact volume of MACRILEN solution to be administered and transfer the required volume of MACRILEN solution into a drinking glass.

Administer the MACRILEN solution and perform the test:

j.
Have the patient being tested drink the entire volume of MACRILEN solution in the drinking glass (i.e., the dose) within 30 seconds.
k.
Observe the patient being tested per routine for the duration of the test.
l.
Draw venous blood samples for GH determination at 30 minutes, 45 minutes, 60 minutes and 90 minutes after administration of MACRILEN.
m.
Prepare serum samples and send to a laboratory for growth hormone determinations.

2.4 Interpretation of MACRILEN Test Results

Clinical studies have established that a maximally stimulated serum GH level of less than 2.8 ng/mL (i.e., at the 30, 45, 60 and 90 minute timepoints) following MACRILEN administration confirms the presence of adult growth hormone deficiency.

3 DOSAGE FORMS AND STRENGTHS

For oral solution: 60 mg white to off-white granules in a pouch for reconstitution in 120 mL of water, resulting in a solution of 0.5 mg/mL of macimorelin.

4 CONTRAINDICATIONS

None

5 WARNINGS AND PRECAUTIONS

5.1 QT Prolongation

MACRILEN causes an increase of about 11 msec in the corrected QT (QTc) interval [see Clinical Pharmacology (12.2)]. QT prolongation can lead to development of torsade de pointes-type ventricular tachycardia with the risk increasing as the degree of prolongation increases. The concomitant use of MACRILEN with drugs that are known to prolong the QT interval should be avoided [see Dosage and Administration (2.2) and Drug Interactions (7.1)].

5.2 Potential for False Positive Test Results with Use of Strong CYP3A4 Inducers

Concomitant use of strong CYP3A4 inducers with MACRILEN can decrease macimorelin plasma levels significantly and thereby lead to a false positive result [see Drug Interactions (7.2)]. Strong CYP3A4 inducers should be discontinued and enough time should be given to allow washout of CYP3A4 inducers prior to test administration [see Dosage and Administration (2.2)].

5.3 Potential for False Negative Test Results in Recent Onset Hypothalamic Disease

Adult growth hormone (GH) deficiency caused by a hypothalamic lesion may not be detected early in the disease process. Macimorelin acts downstream from the hypothalamus and macimorelin stimulated release of stored GH reserves from the anterior pituitary could produce a false negative result early when the lesion involves the hypothalamus. Repeat testing may be warranted in this situation.

6 ADVERSE REACTIONS

6.1 Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.

The data in Table 1 are derived from an open-label, randomized, cross-over study that compared the diagnostic performance of MACRILEN to the insulin tolerance test (ITT) for the diagnosis of adult growth hormone deficiency [see Clinical Studies (14)]. A total of 154 subjects with a high to low pre-test probability of having adult growth hormone deficiency received a single oral dose of 0.5 mg/kg MACRILEN. Out of 154 subjects, 58% were male, 42% female, and 86% of white origin. Median values were for age 41 years (range: 18 – 66 years) and body mass index was 27.5 kg/m2 (range: 16 – 40 kg/m2). Common adverse reactions presented in Table 1 were adverse reactions that were not present at baseline and occurred during MACRILEN dosing in at least two individuals.

Table 1: Common Adverse Reactions Reported in at Least Two Individuals Dosed with MACRILEN in an Open-Label Study

Number of Subjects
(n = 154)

Proportion of Subjects
(%)

Dysgeusia

7

4.5

Dizziness

6

3.9

Headache

6

3.9

Fatigue

6

3.9

Nausea

5

3.2

Hunger

5

3.2

Diarrhea

3

1.9

Upper respiratory tract infection

3

1.9

Feeling hot

2

1.3

Hyperhidrosis

2

1.3

Nasopharyngitis

2

1.3

Sinus bradycardia

2

1.3

Page 1 of 4 1 2 3 4

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.